AN2 Therapeutics, Inc. (NASDAQ: ANTX)

AN2 Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company’s pipeline includes three Phase 2 studies expected to initiate in 2026, two preclinical candidates, and advanced research programs in oncology, bone disorders, and infectious diseases. The company operates in the biotechnology industry, targeting hematologic diseases, infectious diseases, and oncology.

AN2 Therapeutics generates revenue primarily through licensing agreements, milestone payments, and royalties from partners, as well as grant funding for its global health programs. The company has entered into agreements with Anacor Pharmaceuticals and Brii Biosciences that provide upfront payments, potential milestone payments contingent on development and commercial achievements, and tiered royalties on net sales of licensed products. Additionally, support from organizations such as the Adjuvant Global Health Technology Fund and government grants funds research activities for diseases like melioidosis and tuberculosis.

The company operates through the following segments: Hematologic Diseases, Infectious Diseases, and Oncology.

• Hematologic Diseases: This segment focuses on developing oral epetraborole for polycythemia vera, a blood cancer characterized by overproduction of red blood cells, with a Phase 2 trial planned for initiation in 2026.

• Infectious Diseases: This segment advances epetraborole for Mycobacterium abscessus complex lung disease and AN2-502998 for Chagas disease, alongside global health programs targeting melioidosis and tuberculosis through nondilutive funding.

• Oncology: This segment pursues preclinical programs targeting PI3Kα and ENPP1 to develop selective inhibitors aimed at overcoming limitations of existing therapies and enhancing immune mediated tumor clearance.

AN2 Therapeutics positions itself as an innovative player in the niche of boron based small molecule therapeutics, competing with larger biopharmaceutical firms that pursue similar disease areas but often rely on different chemical modalities. Its competitive advantage lies in the proprietary boron chemistry platform, which enables distinct target engagement and may improve safety profiles relative to existing treatments. While facing competition from established companies with approved therapies for polycythemia vera, Mycobacterium abscessus, and Chagas disease, the company’s focus on unmet medical needs and potential for first in class oral agents differentiates its approach.

As a prerevenue clinical stage company, AN2 Therapeutics does not yet serve commercial customers; its future customers are expected to include patients with polycythemia vera, Mycobacterium abscessus lung disease, and Chagas disease, as well as healthcare providers and hospitals that would prescribe its approved therapies. In the near term, the company collaborates with partners such as Anacor Pharmaceuticals, Brii Biosciences, Adjuvant Global Health Technology Fund, the University of Georgia Research Foundation, and Oregon Health and Sciences University to advance its research and development programs.